4th Quarter - Report

TARPLIN STRATEGIES LLC for GENENTECH, INC.

Firm
Client
Income
$75,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

Public Law 111-148, the Patient Protection and Affordable Care Act of 2009 - Implementation issues related to the authorization for comparative effectiveness research and the the Patient-Centered Outcomes Research Institute.

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families.

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); SENATE; Food & Drug Administration (FDA)

Health Issues HCR

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families

Contacted: Executive Office of the President (EOP); SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Medicare/Medicaid MMM

Public Law 111-148, the Patient Protection and Affordable Care Act - Medicare and Medicaid reimbursement for biotherapeutics. H.R. 4213, the American Jobs, Closing Tax Loopholes and Preventing Outsourcing Act of 2010 - eligibility changes for the 340B program, treatment of certain drugs for computation of Average Manufacturer's Price under the Medicaid program. Participated in discussions with Senate Aging Comm staff on Medicare coverage/payment issues related to cancer biotherapeutics.

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families.

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Bills named: H.R. 4213 (111th)

Pharmacy PHA

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program, structure of the Medicare prescription drug benefit. H.R. 4213, the American Jobs, Closing Tax Loopholes and Preventing Outsourcing Act of 2010 - eligibility changes related to the 340B program, treatment of certain drugs for computation of Average Manufacturer's Price under the Medicaid program. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid reimbursement, fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription drug benefit. General issues related to FDA approval and CMS coverage decisions regarding Avastin and Lucentis.

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families

Contacted: SENATE; Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 4213 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.